EntreMed to Present at BioPartnering Europe Conference
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Mr. Bliss will provide an overview of the Company's clinical-stageprograms, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoidarthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for thetreatment of cancer, is in a multi-center Phase 1b dose-escalation study inpatients with solid tumors. Panzem(R) (2ME2), an orally-active small moleculeangiogenesis inhibitor with disease modifying properties for the treatment ofrheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthyvolunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA toprospective pharmaceutical and biotech company partners as a means toaccelerate the development and commercialization of these novel drugcandidates.
Mr. Bliss's presentation will not be web cast; however, a copy of hispresentation will be available through the Company's web site athttp://www.entremed.com.
EntreMed, Inc. is a clinical-stage pharmaceutical company developingtherapeutic candidates primarily for the treatment of cancer and inflammation.MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, iscurrently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novelantimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1studies in advanced cancers. The Company also has an approved IND applicationfor Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop andcommercialize new compounds based on the Company's expertise in angiogenesis,cell cycle regulation, cell signaling and inflammation -- processes vital tothe treatment of cancer and other diseases, such as rheumatoid arthritis.Additional information about EntreMed is available on the Company's web siteat http://www.entremed.com and in various filings with the Securities andExchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act with respect to the outlook forexpectations for future financial or business performance (including thetiming of royalty revenues and future R&D expenditures), strategies,expectations and goals. Forward-looking statements are subject to numerousassumptions, risks and uncertainties, which change over time. Forward-lookingstatements speak only as of the date they are made, and no duty to updateforward-looking statements is assumed. Actual results could differ materiallyfrom those currently anticipated due to a number of factors, including thoseset forth in Securities and Exchange Commission filings under "Risk Factors,"including risks relating to the need for additional capital and theuncertainty of additional funding; variations in actual sales of Thalomid(R),risks associated with the Company's product candidates; the early-stageproducts under development; results in preclinical models are not necessarilyindicative of clinical results, uncertainties relating to preclinical andclinical trials; success in the clinical development of any products;dependence on third parties; future capital needs; and risks relating to thecommercialization, if any, of the Company's proposed products (such asmarketing, safety, regulatory, patent, product liability, supply, competitionand other risks).CONTACT: Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
SOURCE EntreMed, Inc.
You May Also Like